{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:26:12Z","timestamp":1790108772895,"version":"4.0.1"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:00:00Z","timestamp":1625875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche Ltd.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003803","name":"University of Hong Kong","doi-asserted-by":"publisher","award":["202009185062"],"award-info":[{"award-number":["202009185062"]}],"id":[{"id":"10.13039\/501100003803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prompt antiviral treatment has the potential to reduce influenza virus transmission to close contacts, but rigorous data on the magnitude of treatment effects on transmission are limited. Animal model data indicate that rapid reductions in viral replication after antiviral treatment reduce the risk of transmission. Observational and clinical trial data with oseltamivir and other neuraminidase inhibitors indicate that prompt treatment of household index patients seems to reduce the risk of illness in contacts, although the magnitude of the reported effects has varied widely across studies. In addition, the potential risk of transmitting drug-resistant variants exists with all approved classes of influenza antivirals. A controlled trial examining baloxavir treatment efficacy to reduce transmission, including the risk of transmitting virus with reduced baloxavir susceptibility, is currently in progress. If reduced transmission risk is confirmed, modeling studies indicate that early treatment could have major epidemiologic benefits in seasonal and pandemic influenza.<\/jats:p>","DOI":"10.1093\/cid\/ciab625","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T15:14:23Z","timestamp":1625843663000},"page":"532-540","source":"Crossref","is-referenced-by-count":44,"title":["Reducing Influenza Virus Transmission: The Potential Value of Antiviral Treatment"],"prefix":"10.1093","volume":"74","author":[{"given":"Frederick G","family":"Hayden","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Virginia School of Medicine, Charlottesville, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Asher","sequence":"additional","affiliation":[{"name":"Leidos, Reston, Virginia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J","family":"Cowling","sequence":"additional","affiliation":[{"name":"School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeron C","family":"Hurt","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Ikematsu","sequence":"additional","affiliation":[{"name":"Ricerca Clinica, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Kuhlbusch","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Lemenuel-Diot","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanwei","family":"Du","sequence":"additional","affiliation":[{"name":"School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren Ancel","family":"Meyers","sequence":"additional","affiliation":[{"name":"Departments of Integrative Biology and Statistics & Data Sciences, University of Texas, Austin, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro A","family":"Piedra","sequence":"additional","affiliation":[{"name":"Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Takazono","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Ling","family":"Yen","sequence":"additional","affiliation":[{"name":"School of Public Health, The University of Hong Kong, Hong Kong Special Administrative Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold S","family":"Monto","sequence":"additional","affiliation":[{"name":"University of Michigan School of Public Health, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,10]]},"reference":[{"key":"2022021117153795100_CIT0001","first-page":"1009","article-title":"Influenza virus","volume-title":"Clinical virology","author":"Hayden","year":"2017","edition":"4th ed"},{"key":"2022021117153795100_CIT0002","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3201\/eid2605.190994","article-title":"Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings\u2014personal protective and environmental measures","volume":"26","author":"Xiao","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2022021117153795100_CIT0003","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3201\/eid2605.190995","article-title":"Nonpharmaceutical measures for pandemic influenza in nonhealthcare settings\u2014social distancing measures","volume":"26","author":"Fong","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"2022021117153795100_CIT0004","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41591-020-0843-2","article-title":"Respiratory virus shedding in exhaled breath and efficacy of face masks","volume":"26","author":"Leung","year":"2020","journal-title":"Nat Med"},{"key":"2022021117153795100_CIT0005","article-title":"Which influenza viruses will emerge following the SARS-CoV-2 pandemic?","author":"Laurie","journal-title":"Influenza Other Respir Viruses"},{"key":"2022021117153795100_CIT0006","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1915341","article-title":"Baloxavir marboxil for prophylaxis against influenza in household contacts","volume":"383","author":"Ikematsu","year":"2020","journal-title":"N Engl J Med"},{"key":"2022021117153795100_CIT0007","doi-asserted-by":"crossref","first-page":"e113633","DOI":"10.1371\/journal.pone.0113633","article-title":"Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies","volume":"9","author":"Okoli","year":"2014","journal-title":"PLoS One"},{"key":"2022021117153795100_CIT0008","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1093\/jac\/dku146","article-title":"Evaluation of oseltamivir prophylaxis regimens for reducing influenza virus infection, transmission and disease severity in a ferret model of household contact","volume":"69","author":"Oh","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2022021117153795100_CIT0009","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.virol.2015.06.020","article-title":"Oseltamivir inhibits influenza virus replication and transmission following ocular-only aerosol inoculation of ferrets","volume":"484","author":"Belser","year":"2015","journal-title":"Virology"},{"key":"2022021117153795100_CIT0010","doi-asserted-by":"crossref","first-page":"e1008395","DOI":"10.1371\/journal.ppat.1008395","article-title":"Baloxavir treatment of ferrets infected with influenza A(H1N1)pdm09 virus reduces onward transmission","volume":"16","author":"Lee","year":"2020","journal-title":"PLoS Pathog"},{"key":"2022021117153795100_CIT0011","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/v12020167","article-title":"A broad and potent H1-specific human monoclonal antibody produced in plants prevents influenza virus infection and transmission in guinea pigs","volume":"12","author":"Park","year":"2020","journal-title":"Viruses"},{"key":"2022021117153795100_CIT0012","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0166-3542(01)00214-5","article-title":"Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets","volume":"54","author":"Herlocher","year":"2002","journal-title":"Antiviral Res"},{"key":"2022021117153795100_CIT0013","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1086\/424572","article-title":"Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets","volume":"190","author":"Herlocher","year":"2004","journal-title":"J Infect Dis"},{"key":"2022021117153795100_CIT0014","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1126\/science.1187816","article-title":"Permissive secondary mutations enable the evolution of influenza oseltamivir resistance","volume":"328","author":"Bloom","year":"2010","journal-title":"Science"},{"key":"2022021117153795100_CIT0015","doi-asserted-by":"crossref","first-page":"7268","DOI":"10.1128\/JVI.07242-12","article-title":"Enhanced mammalian transmissibility of seasonal influenza A\/H1N1 viruses encoding an oseltamivir-resistant neuraminidase","volume":"86","author":"Bouvier","year":"2012","journal-title":"J Virol"},{"key":"2022021117153795100_CIT0016","doi-asserted-by":"crossref","first-page":"e1002431","DOI":"10.1371\/journal.ppat.1002431","article-title":"Role of permissive neuraminidase mutations in influenza A\/Brisbane\/59\/2007-like (H1N1) viruses","volume":"7","author":"Abed","year":"2011","journal-title":"PLoS Pathog"},{"key":"2022021117153795100_CIT0017","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/infdis\/jis337","article-title":"Characteristics of a widespread community cluster of H275Y oseltamivir-resistant A(H1N1)pdm09 influenza in Australia","volume":"206","author":"Hurt","year":"2012","journal-title":"J Infect Dis"},{"key":"2022021117153795100_CIT0018","doi-asserted-by":"crossref","first-page":"e1004065","DOI":"10.1371\/journal.ppat.1004065","article-title":"Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses","volume":"10","author":"Butler","year":"2014","journal-title":"PLoS Pathog"},{"key":"2022021117153795100_CIT0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41564-019-0609-0","article-title":"Influenza A variants with reduced susceptibility to baloxavir isolated from Japanese patients are fit and transmit through respiratory droplets","volume":"5","author":"Imai","year":"2020","journal-title":"Nat Microbiol"},{"key":"2022021117153795100_CIT0020","doi-asserted-by":"crossref","first-page":"8593","DOI":"10.1073\/pnas.1916825117","article-title":"Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility","volume":"117","author":"Jones","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022021117153795100_CIT0021","doi-asserted-by":"crossref","first-page":"e1009527","DOI":"10.1371\/journal.ppat.1009527","article-title":"Evaluating the fitness of PA\/I38T-substituted influenza A viruses with reduced baloxavir susceptibility in a competitive mixtures ferret model","volume":"17","author":"Lee","year":"2021","journal-title":"PLoS Pathog"},{"key":"2022021117153795100_CIT0022","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1086\/650458","article-title":"Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus","volume":"50","author":"Ng","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2022021117153795100_CIT0023","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/1471-2334-10-211","article-title":"Oseltamivir for treatment and prevention of pandemic influenza A\/H1N1 virus infection in households, Milwaukee, 2009","volume":"10","author":"Goldstein","year":"2010","journal-title":"BMC Infect Dis"},{"key":"2022021117153795100_CIT0024","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/147323001103900231","article-title":"Household transmission of influenza (H1N1-2009) in Japan: age-specificity and reduction of household transmission risk by zanamivir treatment","volume":"39","author":"Nishiura","year":"2011","journal-title":"J Int Med Res"},{"key":"2022021117153795100_CIT0025","doi-asserted-by":"crossref","first-page":"e31519","DOI":"10.1371\/journal.pone.0031519","article-title":"Risk factors of household transmission of pandemic (H1N1) 2009 among patients treated with antivirals: a prospective study at a primary clinic in Japan","volume":"7","author":"Hirotsu","year":"2012","journal-title":"PLoS One"},{"key":"2022021117153795100_CIT0026","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jiac.2014.01.012","article-title":"Spread of viral infection to family members from influenza patients treated with a neuraminidase inhibitor","volume":"20","author":"Nakano","year":"2014","journal-title":"J Infect Chemother"},{"key":"2022021117153795100_CIT0027","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1473-3099(15)70041-1","article-title":"Effects of oseltamivir treatment of index patients with influenza on secondary household illness in an urban setting in Bangladesh: secondary analysis of a randomised, placebo-controlled trial","volume":"15","author":"Fry","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2022021117153795100_CIT0028","doi-asserted-by":"crossref","first-page":"e859","DOI":"10.1093\/cid\/ciaa1622","article-title":"Comparison of household transmission of influenza virus from index patients treated with baloxavir marboxil or neuraminidase inhibitors: a health insurance claims database study","volume":"72","author":"Komeda","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2022021117153795100_CIT0029","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/infdis\/153.3.431","article-title":"Influenza: its control in persons and populations","volume":"153","author":"Couch","year":"1986","journal-title":"J Infect Dis"},{"key":"2022021117153795100_CIT0030","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJM198912213212502","article-title":"Emergence and apparent transmission of rimantadine-resistant influenza A virus in families","volume":"321","author":"Hayden","year":"1989","journal-title":"N Engl J Med"},{"key":"2022021117153795100_CIT0031","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/aje\/kwj362","article-title":"Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials","volume":"165","author":"Halloran","year":"2007","journal-title":"Am J Epidemiol"},{"key":"2022021117153795100_CIT0032","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3851\/IMP2128","article-title":"Effect of oseltamivir, zanamivir or oseltamivir-zanamivir combination treatments on transmission of influenza in households","volume":"17","author":"Carrat","year":"2012","journal-title":"Antivir Ther"},{"key":"2022021117153795100_CIT0033","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40780-020-00178-4","article-title":"Efficacy of baloxavir marboxil on household transmission of influenza infection","volume":"6","author":"Umemura","year":"2020","journal-title":"J Pharm Health Care Sci"},{"key":"2022021117153795100_CIT0034","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N Engl J Med"},{"key":"2022021117153795100_CIT0035","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S1473-3099(20)30004-9","article-title":"Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Ison","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2022021117153795100_CIT0036","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/INF.0000000000002747","article-title":"Baloxavir marboxil single-dose treatment in influenza-infected children: a randomized, double-blind, active controlled phase 3 safety and efficacy trial (miniSTONE-2)","volume":"39","author":"Baker","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"2022021117153795100_CIT0037","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3201\/eid2511.190757","article-title":"Human-to-human transmission of influenza A(H3N2) virus with reduced susceptibility to baloxavir, Japan, February 2019","volume":"25","author":"Takashita","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2022021117153795100_CIT0038","doi-asserted-by":"crossref","first-page":"1900170","DOI":"10.2807\/1560-7917.ES.2019.24.12.1900170","article-title":"Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019","volume":"24","author":"Takashita","year":"2019","journal-title":"Euro Surveill"},{"key":"2022021117153795100_CIT0039","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/bcp.13229","article-title":"Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics","volume":"83","author":"Kamal","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2022021117153795100_CIT0040","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1371\/journal.pmed.0040015","article-title":"Antiviral Resistance and the Control of Pandemic Influenza","volume":"4","author":"Lipsitch","year":"2007","journal-title":"PLoS Med"},{"key":"2022021117153795100_CIT0041","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nature04017","article-title":"Strategies for containing an emerging influenza pandemic in Southeast Asia","volume":"437","author":"Ferguson","year":"2005","journal-title":"Nature"},{"key":"2022021117153795100_CIT0042","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/aje\/kwm375","article-title":"Time lines of infection and disease in human influenza: a review of volunteer challenge studies","volume":"167","author":"Carrat","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2022021117153795100_CIT0043","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1038\/s41467-020-16585-y","article-title":"Modeling mitigation of influenza epidemics by baloxavir","volume":"11","author":"Du","year":"2020","journal-title":"Nat Commun"},{"key":"2022021117153795100_CIT0044","article-title":"Novel model to determine how influenza viral shedding correlates with infectiousness and to predict the impact of antivirals on reduction of influenza transmission","volume-title":"The 7th ESWI Influenza Conference, 6\u20139 December 2020","author":"Asher"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab625\/40394338\/ciab625.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/74\/3\/532\/42499688\/ciab625.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/74\/3\/532\/42499688\/ciab625.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T12:19:30Z","timestamp":1644581970000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/74\/3\/532\/6318823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,10]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,7,10]]},"published-print":{"date-parts":[[2022,2,11]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab625","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,7,10]]}}}